Candida auris from the Egyptian cobra: Role of snakes as potential reservoirs.

IF 2.7 3区医学 Q3 INFECTIOUS DISEASES

Medical mycology Pub Date : 2024-07-04 DOI:10.1093/mmy/myae056

Claudia Cafarchia, Jairo A Mendoza-Roldan, Wafa Rhimi, Iniobong C I Ugochukwu, Mara Miglianti, Frederic Beugnet, Letterio Giuffrè, Orazio Romeo, Domenico Otranto

引用次数: 0

Abstract

Candida auris represents one of the most urgent threats to public health, although its ecology remains largely unknown. Because amphibians and reptiles may present favorable conditions for C. auris colonization, cloacal and blood samples (n = 68), from several snake species, were cultured and molecularly screened for C. auris using molecular amplification of glycosylphosphatidylinositol protein-encoding genes and ribosomal internal transcribed spacer sequencing. Candida auris was isolated from the cloacal swab of one Egyptian cobra (Naja haje legionis) and molecularly identified in its cloaca and blood. The isolation of C. auris from wild animals is herein reported for the first time, thus suggesting the role that these animals could play as reservoirs of this emerging pathogen. The occurrence of C. auris in blood requires further investigation, although the presence of cationic antimicrobial peptides in the plasma of reptiles could play a role in reducing the vitality of the fungus.

查看原文本刊更多论文

埃及眼镜蛇身上的念珠菌：蛇作为潜在贮藏体的作用。

念珠菌是对公共卫生最紧迫的威胁之一，但其生态学在很大程度上仍不为人所知。由于两栖类和爬行类动物可能为白色念珠菌的定植提供了有利条件，因此对来自几种蛇类的泄殖腔和血液样本（n = 68）进行了培养，并利用糖基磷脂酰肌醇（GPI）蛋白编码基因的分子扩增和核糖体内部转录间隔（ITS）测序对白色念珠菌进行了分子筛选。从一条埃及眼镜蛇（Naja haje legionis）的泄殖腔拭子中分离出了念珠菌，并在其泄殖腔和血液中进行了分子鉴定。本文首次报道了从野生动物中分离出念珠菌，从而表明这些动物可能是这一新兴病原体的贮藏地。尽管爬行动物血浆中存在阳离子抗菌肽（CAMPs）可能会降低真菌的活力，但血液中是否存在 C. auris 还需要进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical mycology 医学-兽医学

CiteScore

5.70

自引率

3.40%

发文量

632

审稿时长

12 months

期刊介绍： Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.